Logo

Aarvik Therapeutics Signs a Research Collaboration with ArriVent Biopharma to Develop and Commercialize Novel Cancer Therapeutic

Share this

Aarvik Therapeutics Signs a Research Collaboration with ArriVent Biopharma to Develop and Commercialize Novel Cancer Therapeutic

Shots:

  • Aarvik to receive $100M up front, research funding, option fees & is also eligible to receive development and commercial milestones along with royalties
  • The collaboration will use ArriVent’s global development expertise with Aarvik’s modular Ab platform to advance novel cancer therapeutics
  • Under the terms of collaboration, Aarvik is responsible for the discovery and preclinical development of the novel molecule based on its modular platform that combines multiple target mechanisms while ArriVent will lead the clinical development and commercialization of the drug candidate

Ref: Businesswire | Image: Aarvik 

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions